Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7

Gareth J. Inman, Francisco J. Nicolás, James F. Callahan, John D. Harling, Laramie M. Gaster, Alastair D. Reith, Nicholas J. Laping and Caroline S. Hill
Molecular Pharmacology July 2002, 62 (1) 65-74; DOI: https://doi.org/10.1124/mol.62.1.65
Gareth J. Inman
1 2 3 4 5 6
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francisco J. Nicolás
1 2 3 4 5 6
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James F. Callahan
1 2 3 4 5 6
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John D. Harling
1 2 3 4 5 6
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laramie M. Gaster
1 2 3 4 5 6
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alastair D. Reith
1 2 3 4 5 6
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas J. Laping
1 2 3 4 5 6
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline S. Hill
1 2 3 4 5 6
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 62 no. 1 65-74
DOI 
https://doi.org/10.1124/mol.62.1.65
PubMed 
12065756

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Received November 28, 2001
  • Accepted March 21, 2002
  • Published online July 1, 2002.

Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Gareth J. Inman1,
  2. Francisco J. Nicolás1,
  3. James F. Callahan2,
  4. John D. Harling3,
  5. Laramie M. Gaster4,
  6. Alastair D. Reith5,
  7. Nicholas J. Laping6, and
  8. Caroline S. Hill1
  1. 1Laboratory of Developmental Signalling, Cancer Research UK London Research Institute, Lincoln's Inn Fields Laboratories, London, UK (G.J.I., F.J.N., C.S.H.); 2Department of Medicinal Chemistry, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania (J.F.C.); 3Department of Medicinal Chemistry, GlaxoSmithKline Pharmaceuticals, Stevenage, Hertfordshire, UK (J.D.H.); 4Department of High-Throughput Chemistry (L.M.G.) and 5High-Throughput Biology (A.D.R.), GlaxoSmithKline Pharmaceuticals, Harlow, Essex, UK; and 6Renal and Urology Research, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (N.J.L.)
  1. Dr. Caroline Hill, Laboratory of Developmental Signalling, Cancer Research UK London Research Institute, Lincoln's Inn Fields Laboratories, 44 Lincoln's Inn Fields, London WC2A 3PX, UK. E-mail: caroline.hill{at}cancer.org.uk
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: June 2002 to February 2023

AbstractFullPdf
Jun 200265170248
Jul 200225191176
Aug 2002811493
Sep 20026144112
Oct 2002712191
Nov 200269375
Dec 200238660
Jan 20031010186
Feb 200388553
Mar 200358575
Apr 2003119089
May 200398472
Jun 200327454
Jul 2003157570
Aug 2003237744
Sep 2003208184
Oct 2003139392
Nov 2003327899
Dec 2003249586
Jan 200429143108
Feb 20042311187
Mar 2004439982
Apr 20041812070
May 2004198447
Jun 200460163112
Jul 20043512471
Aug 20042611477
Sep 20043311378
Oct 20044012378
Nov 20041910263
Dec 2004268952
Jan 20053415976
Feb 20054110879
Mar 20053012684
Apr 2005219353
May 2005366647
Jun 20052911082
Jul 2005109469
Aug 2005198463
Sep 2005267251
Oct 2005229973
Nov 20054811085
Dec 2005287652
Jan 2006309768
Feb 2006309163
Mar 20062111555
Apr 2006217660
May 2006316957
Jun 2006207967
Jul 2006346859
Aug 2006239272
Sep 2006317558
Oct 2006328898
Nov 2006479969
Dec 2006277340
Jan 2007368459
Feb 2007357864
Mar 2007327666
Apr 2007388765
May 2007327672
Jun 2007277044
Jul 2007369069
Aug 2007659271
Sep 2007449476
Oct 20073610368
Nov 20074310271
Dec 2007265047
Jan 2008297749
Feb 2008177356
Mar 2008496350
Apr 2008379272
May 2008609678
Jun 2008348048
Jul 2008689064
Aug 20081119950
Sep 2008127130134
Oct 20081119969
Nov 2008140143165
Dec 20089811070
Jan 200910614675
Feb 200911512477
Mar 2009180152102
Apr 2009169120122
May 2009126120103
Jun 200912611991
Jul 200915613381
Aug 200918411585
Sep 200915312472
Oct 2009277160108
Nov 200925812172
Dec 20092068384
Jan 201023111694
Feb 201025612680
Mar 2010251124107
Apr 2010224173102
May 201021314786
Jun 201016917588
Jul 201018814995
Aug 2010234135106
Sep 2010226164111
Oct 201021313099
Nov 2010240145112
Dec 2010192136101
Jan 201120914391
Feb 201124513996
Mar 2011238142141
Apr 2011216128124
May 2011199128161
Jun 2011182150106
Jul 2011210108125
Aug 2011194145143
Sep 2011226159116
Oct 2011244173125
Nov 2011269153127
Dec 2011246149137
Jan 2012247184141
Feb 2012236161110
Mar 2012259170128
Apr 2012279178139
May 2012261160121
Jun 201219314797
Jul 2012148215111
Aug 201215014795
Sep 2012123172110
Oct 2012137179143
Nov 2012115166123
Dec 2012115150103
Jan 2013143184136
Feb 2013119215139
Mar 2013126196113
Apr 2013145150103
May 2013123147107
Jun 2013100164114
Jul 2013119144110
Aug 20131278592
Sep 2013132141120
Oct 2013190178125
Nov 2013138178125
Dec 2013113180115
Jan 2014156162101
Feb 2014109160100
Mar 2014161220120
Apr 2014130207125
May 2014131177111
Jun 2014125194110
Jul 2014110204102
Aug 20148815393
Sep 201491205117
Oct 2014118258102
Nov 201412821684
Dec 201415916880
Jan 201510418087
Feb 20159422295
Mar 2015147232385
Apr 2015177259113
May 2015170282132
Jun 2015151244108
Jul 201514120482
Aug 201510315375
Sep 201510314188
Oct 2015114191138
Nov 20158718677
Dec 20159118578
Jan 201616319484
Feb 201621916868
Mar 2016179262109
Apr 2016139240102
May 201610325596
Jun 201612919376
Jul 201699225114
Aug 2016126232103
Sep 20169426299
Oct 201641489103
Nov 201650366113
Dec 20162327063
Jan 20171824062
Feb 20173024183
Mar 20172332180
Apr 20171622345
May 20171622672
Jun 20171715549
Jul 20172619163
Aug 20171626267
Sep 20171924666
Oct 20171620370
Nov 20171224660
Dec 20171721757
Jan 20181327085
Feb 20181815568
Mar 20182023983
Apr 20182236770
May 20182221186
Jun 20181219969
Jul 20181416884
Aug 20181619473
Sep 2018717854
Oct 20182015966
Nov 20182020076
Dec 20181687749
Jan 20192296827
Feb 20192536534
Mar 20192156728
Apr 20193327937
May 20192447330
Jun 20191864925
Jul 20192007128
Aug 201924910426
Sep 201933010115
Oct 201919810837
Nov 20192425919
Dec 20191795023
Jan 20202568630
Feb 20202015118
Mar 20202495024
Apr 20202174019
May 20202144226
Jun 20201223010
Jul 20201373820
Aug 20201224018
Sep 20201473411
Oct 20201502811
Nov 20201663416
Dec 20202213411
Jan 20212035235
Feb 20211875020
Mar 20212996439
Apr 20212264412
May 20212522812
Jun 20211855624
Jul 20211465015
Aug 2021205319
Sep 20211556621
Oct 20211554927
Nov 20212014925
Dec 20211733413
Jan 20222143615
Feb 20222294025
Mar 20222485327
Apr 20222234723
May 20222105327
Jun 20221955116
Jul 20221944515
Aug 20221973320
Sep 20221782219
Oct 20222873221
Nov 20223312411
Dec 20223113316
Jan 20233096624
Feb 20234344

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 62 (1)
Molecular Pharmacology
Vol. 62, Issue 1
1 Jul 2002
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7

Gareth J. Inman, Francisco J. Nicolás, James F. Callahan, John D. Harling, Laramie M. Gaster, Alastair D. Reith, Nicholas J. Laping and Caroline S. Hill
Molecular Pharmacology July 1, 2002, 62 (1) 65-74; DOI: https://doi.org/10.1124/mol.62.1.65

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7

Gareth J. Inman, Francisco J. Nicolás, James F. Callahan, John D. Harling, Laramie M. Gaster, Alastair D. Reith, Nicholas J. Laping and Caroline S. Hill
Molecular Pharmacology July 1, 2002, 62 (1) 65-74; DOI: https://doi.org/10.1124/mol.62.1.65
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The binding site for KCI807 in the androgen receptor
  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics